Thomas P. Conrads

The paper identifies CLDN3 as a tumor-selective target in SCLC using proteogenomic analysis and validates its therapeutic potential with a monoclonal antibody.

This study shows ATR kinase inhibitors cause mitochondrial fission and impair immune memory in CD8+ T cells during viral infection.

ShapeUpLMD automates ROI optimization for laser microdissection, improving tumor purity and spatial accuracy in multi-omic tissue profiling.

This study uses proteogenomics to identify ancestry-specific and shared molecular drivers in prostate cancer, revealing distinct biological programs and improving risk prediction.

The paper identifies conserved protein alterations and elevated MUC16 in low-grade serous ovarian cancers through quantitative proteomics and validation across multiple datasets.

The paper uses laser microdissection and proteomics to compare tumor and stroma in HNSCC tissues, identifying ECM enrichment in stroma and potential targets for disease intervention.

This study maps the SCLC tumor microenvironment and identifies cancer-associated fibroblasts as key drivers of neuroendocrine state plasticity and poor prognosis.

ProteoMixture estimates cell type proportions in bulk tissue proteomics data using optimized protein signatures validated on high-grade serous ovarian cancer samples.

The paper describes a modified dual preparatory method to improve RNA yield from laser microdissected human cancer tissue samples.

This study examines the relationship between genetic ancestry, somatic mutation frequency, and histologic subtypes in high-grade endometrial cancer, finding associations between local ancestry and tumor mutation burden and histologic subtypes.

This paper standardizes a proteotype analysis workflow across multiple international sites to enable distributed, reproducible proteomic data generation for precision medicine.

This study shows that Cdk2 is required for platelet activation by inhibiting PP1 phosphatase activity and promoting Erk activation through phosphorylation of PPP1R12a.

This study identifies HN1 as a predictive and pharmacodynamic biomarker of metformin response in endometrioid endometrial cancer, showing it is elevated in responders and decreases after treatment.